Greenland Mines Ltd. (NASDAQ: GRML) announced that Innovation, Science and Economic Development Canada has granted a patent covering technology exclusively licensed by the company for Klotho-based gene therapies targeting cognition, memory and neurodegenerative diseases. The patent protects the use of the secreted Klotho (“s-KL”) RNA splice variant in genetic therapies and includes 42 claims covering its synthesis, delivery methods and potential application across multiple neurological disorders, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis.
The company said the Canadian patent expands its intellectual property portfolio for Klotho-based therapeutics and complements previously issued patents in the United States, China and Europe. Greenland Mines added that process development and manufacturing for lead candidate KLTO-101 is scheduled to begin in August 2026, while KLTO-202 has advanced to GMP manufacturing as the company prepares for regulatory interactions later this year. To view the full press release, visit https://ibn.fm/x2pHA.
This patent grant is significant because it strengthens Greenland Mines’ position in the rapidly growing gene therapy market, particularly for neurodegenerative diseases that currently lack effective treatments. The Klotho gene has been associated with cognitive function and longevity, and its therapeutic potential could address a substantial unmet medical need. With patent protection in key jurisdictions, the company is better positioned to develop and commercialize its Klotho-based therapies, potentially attracting partnerships or licensing deals.
Greenland Mines is a Nasdaq-listed company with two operating divisions: Mining, focused on the exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of the previously announced transaction, the Sarfartoq neodymium-praseodymium (Nd-Pr) rare earths project in southwest Greenland; and Biotech, including Klotho’s KLTO‑202 primary indication for ALS. The Company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure. The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML.
The advancement of KLTO-202 to GMP manufacturing marks a critical step toward clinical trials, as the company prepares for regulatory interactions later this year. For investors, this development underscores the potential value of the biotech division within Greenland Mines, which may drive future growth beyond its mining operations.
